Literature DB >> 6758908

Comparison of the actions of centrally and peripherally administered clonidine and guanfacine in the rabbit: investigation of the differences.

N D Barber, J L Reid.   

Abstract

1 Guanfacine was administered intravenously to rabbits and produced a dose-dependent lowering of blood pressure. 2 Clonidine and guanfacine, administered to rabbits intravenously (30 micrograms/kg and 300 micrograms/kg respectively) and intracisternally (3 micrograms/kg and 12 micrograms/kg respectively) caused a similar degree of hypotension, apparently of central origin. 3 Saliva flow in vivo was estimated. Clonidine (30 micrograms/kg, i.v.) caused a significant decrease in salivation (P less than 0.05) for the first 50 min after injection. Guanfacine caused a significant fall (P less than 0.05) only at 50 and 180 min after injection. 4 Apparent partition coefficients for an octanol/buffer system at pH 7.4 for clonidine and guanfacine were 5.4 and 21.2 respectively. 5 Measurement of guanfacine levels concurrently in both plasma and brain showed that guanfacine had higher brain than plasma levels and that the brain levels were fairly constant over the 3 h measured. Brain:plasma ratios were 2.1:1, 5.3:1 and 13.6:1 after 15, 90 and 180 min respectively. 6 These results suggest that the long duration of action of guanfacine is due to its persistence at its central site of action.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6758908      PMCID: PMC2044669          DOI: 10.1111/j.1476-5381.1982.tb09342.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  Clinical pharmacology and pharmacokinetics of clonidine.

Authors:  C T Dollery; D S Davies; G H Draffan; H J Dargie; C R Dean; J L Reid; R A Clare; S Murray
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

2.  Centrally acting drugs in antihypertensive therapy.

Authors:  C T Dollery; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

3.  A new centrally action antihypertensive agent guanfacine (BS 100-141).

Authors:  U C Dubach; R Huwyler; P Radielovic; M Singeisen
Journal:  Arzneimittelforschung       Date:  1977

4.  Participation of central noradrenergic neurons in arterial baroreceptor reflexes in the rabbit. A study with intracisternally administered 6-hydroxydopamine.

Authors:  J P Chalmers; J L Reid
Journal:  Circ Res       Date:  1972-11       Impact factor: 17.367

Review 5.  Mini-review. The postsynaptic alpha 2-adrenoreceptor.

Authors:  P B Timmermans; P A van Zwieten
Journal:  J Auton Pharmacol       Date:  1981-03

6.  Substituted phenylacetylguanidines: a new class of antihypertensive agents.

Authors:  J B Bream; H Lauener; C W Picard; G Scholtysik; T G White
Journal:  Arzneimittelforschung       Date:  1975-10

7.  Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141).

Authors:  G Scholtysik; H Lauener; E Eichenberger; H Bürki; R Salzmann; E Müller-Schweinitzer; R Waite
Journal:  Arzneimittelforschung       Date:  1975-10

8.  The physiological disposition of 2(2,6-dichloroanilino)-2-imidazoline (St-155).

Authors:  A K Cho; S H Curry
Journal:  Biochem Pharmacol       Date:  1969-02       Impact factor: 5.858

9.  The clinical pharmacology of clonidine: relationship between plasma concentration and pharmacological effect in animals and man.

Authors:  J L Reid; N D Barber; D S Davies
Journal:  Arch Int Pharmacodyn Ther       Date:  1980

10.  Guanfacine: effects of long-term treatment and withdrawal.

Authors:  J L Reid; C Zamboulis; C A Hamilton
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

  10 in total
  4 in total

1.  The physiological and pharmacological role of presynaptic alpha- and beta-adrenoceptors in man.

Authors:  M J Brown; A D Struthers; J M Burrin; L Di Silvio; D C Brown
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

Review 2.  Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

Review 3.  Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.

Authors:  Henry A Spiller; Hannah L Hays; Alfred Aleguas
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 4.  Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.

Authors:  Michael Huss; Wai Chen; Andrea G Ludolph
Journal:  Clin Drug Investig       Date:  2016-01       Impact factor: 2.859

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.